Scandinavian Biopharma Holding

Executive Summary

Scandinavian Biopharma Holding is a Swedish specialty biopharmaceutical company focused on developing the world's first vaccine against enterotoxigenic E. coli (ETEC)-induced diarrhea, a leading cause of traveler's diarrhea and a significant health burden in endemic regions. The company has built an integrated platform spanning discovery, manufacturing, and commercialization. Its lead candidate, ETEC vaccine, is currently in Phase 3 clinical development, targeting both travelers and populations in low- and middle-income countries. The vaccine has the potential to address a substantial unmet medical need, with the global market for traveler's diarrhea vaccines estimated at over $1 billion annually. Scandinavian Biopharma has secured funding from EU and Swedish innovation agencies and collaborates with global health organizations. If successful, the vaccine could become a standard preventive measure for international travelers and a key tool in reducing childhood diarrhea mortality in endemic areas. The company's robust pipeline also includes immunoglobulin products, providing near-term revenue streams and manufacturing synergies. With a seasoned management team and strong scientific foundation, Scandinavian Biopharma is well-positioned to deliver a groundbreaking vaccine that could transform public health and generate significant commercial value.

Upcoming Catalysts (preview)

• Q4 2026Phase 3 ETEC Vaccine Top-Line Efficacy Data65% success
• Q2 2026Strategic Partnership or Licensing Deal for ETEC Vaccine50% success
• Q3 2026Regulatory Submission or Orphan Drug Designation70% success